Kyowa Kirin International is a part of the Kyowa Hakko Kirin Group, a Japan-based Global Specialty Pharmaceutical Company contributing to human health and well-being, worldwide, through innovative drug discovery and global commercialisation, driven by state-of-the-art antibody technologies in the core therapeutic areas of oncology, nephrology, and immunology.
KKI strives to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies. We are guided by our core values of Commitment to Life, Integrity, Innovation and Teamwork..
While the journey to finding cures to diseases takes immense time and effort – we are not deterred by obstacles or setbacks. Despite these challenges, everyone at KKI is dedicated to leaping forward to make people smile.